Difference between revisions of "BAP1"
Jump to navigation
Jump to search
(Created page with "'''BAP1''', an abbreviation of '''BRCA1-Associated Protein 1''', is an immunostain that is used in the diagnosis of malignant mesothelioma.<ref>{{cite journal |vau...") |
|||
| Line 2: | Line 2: | ||
==Loss of staining== | ==Loss of staining== | ||
*[[Malignant mesothelioma]] | *[[Malignant mesothelioma]] -ve<ref name=pmid29085180>{{cite journal |authors=Pulford E, Huilgol K, Moffat D, Henderson DW, Klebe S |title=Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis? |journal=Dis Markers |volume=2017 |issue= |pages=1310478 |date=2017 |pmid=29085180 |pmc=5612603 |doi=10.1155/2017/1310478 |url=}}</ref> ~57%.<ref name=pmid26226841>{{cite journal |authors=Andrici J, Sheen A, Sioson L, Wardell K, Clarkson A, Watson N, Ahadi MS, Farzin M, Toon CW, Gill AJ |title=Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology |journal=Mod Pathol |volume=28 |issue=10 |pages=1360–8 |date=October 2015 |pmid=26226841 |pmc=4761613 |doi=10.1038/modpathol.2015.87 |url=}}</ref> | ||
==Normal staining== | ==Normal staining== | ||
*[[ | *[[Well-differentiated papillary mesothelial tumour]] - retained (normal) nuclear staining.<ref name=pmid35440764>{{cite journal |authors=Churg A, Galateau-Salle F |title=Well differentiated papillary mesothelial tumor: a new name and new problems |journal=Mod Pathol |volume=35 |issue=10 |pages=1327–1333 |date=October 2022 |pmid=35440764 |doi=10.1038/s41379-022-01082-y |url=}}</ref> | ||
==See also== | ==See also== | ||
Latest revision as of 15:00, 15 September 2025
BAP1, an abbreviation of BRCA1-Associated Protein 1, is an immunostain that is used in the diagnosis of malignant mesothelioma.[1]
Loss of staining
- Malignant mesothelioma -ve[2] ~57%.[3]
Normal staining
- Well-differentiated papillary mesothelial tumour - retained (normal) nuclear staining.[4]
See also
References
- ↑ "BAP1: Not just a BRCA1-associated protein". Cancer Treat Rev 90: 102091. November 2020. doi:10.1016/j.ctrv.2020.102091. PMC 7655689. PMID 32877777. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655689/.
- ↑ Pulford E, Huilgol K, Moffat D, Henderson DW, Klebe S (2017). "Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?". Dis Markers 2017: 1310478. doi:10.1155/2017/1310478. PMC 5612603. PMID 29085180. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612603/.
- ↑ Andrici J, Sheen A, Sioson L, Wardell K, Clarkson A, Watson N, Ahadi MS, Farzin M, Toon CW, Gill AJ (October 2015). "Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology". Mod Pathol 28 (10): 1360–8. doi:10.1038/modpathol.2015.87. PMC 4761613. PMID 26226841. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761613/.
- ↑ Churg A, Galateau-Salle F (October 2022). "Well differentiated papillary mesothelial tumor: a new name and new problems". Mod Pathol 35 (10): 1327–1333. doi:10.1038/s41379-022-01082-y. PMID 35440764.